Effects of housing value and medical subsidy on treatment and outcomes of breast cancer patients in Singapore: A retrospective cohort study.
Breast cancer
Clinical outcomes
Housing value
Medical subsidies
Socioeconomic status
Journal
The Lancet regional health. Western Pacific
ISSN: 2666-6065
Titre abrégé: Lancet Reg Health West Pac
Pays: England
ID NLM: 101774968
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
17
07
2020
revised:
23
10
2020
accepted:
19
11
2020
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
31
7
2021
Statut:
epublish
Résumé
Socioeconomic status (SES) is likely to affect survival in breast cancer patients. Housing value is a reasonable surrogate for SES in Singapore where most residents own their own homes, which could be public (subsidised) or private housing. We evaluated effects of housing value and enhanced medical subsidies on patients' presentation, treatment choices, compliance and survival in a setting of good access to healthcare. A retrospective analysis of breast cancer patients treated in a tertiary hospital cluster from 2000 to 2016 was performed. Individual-level Housing value Index (HI) was derived from each patient's address and then grouped into 3 tiers: HI(high)(minimal subsidy), HI(med)(medium subsidy) and HI(low)(high subsidy). Cox regression was performed to evaluate the associations between overall survival (OS) and cancer-specific survival (CSS) with HI and various factors. We studied a multiracial cohort of 15,532 Stage 0-IV breast cancer patients. Median age was 53.7 years and median follow-up was 7.7 years. Patients with lower HI presented with more advanced disease and had lower treatment compliance. On multivariable analysis, compared to HI(high) patients, HI(med) patients had decreased OS (HR=1.14, 95% CI 1.05-1.23) and CSS (HR=1.15, 95% CI 1.03-1.27), and HI(low) patients demonstrated reduced OS (HR=1.16, 95% CI 1.01-1.33). Ten-year non-cancer mortality was higher in lower HI-strata. Enhanced medical subsidy approximately halved treatment noncompliance rates but its receipt was not an independent prognostic factor for survival. Despite good healthcare access, lower-HI patients have poorer survival from both cancer and non-cancer causes, possibly due to delayed health-seeking and poorer treatment compliance. Enhanced subsidies may mitigate socioeconomic disadvantages. None.
Sections du résumé
BACKGROUND
BACKGROUND
Socioeconomic status (SES) is likely to affect survival in breast cancer patients. Housing value is a reasonable surrogate for SES in Singapore where most residents own their own homes, which could be public (subsidised) or private housing. We evaluated effects of housing value and enhanced medical subsidies on patients' presentation, treatment choices, compliance and survival in a setting of good access to healthcare.
METHODS
METHODS
A retrospective analysis of breast cancer patients treated in a tertiary hospital cluster from 2000 to 2016 was performed. Individual-level Housing value Index (HI) was derived from each patient's address and then grouped into 3 tiers: HI(high)(minimal subsidy), HI(med)(medium subsidy) and HI(low)(high subsidy). Cox regression was performed to evaluate the associations between overall survival (OS) and cancer-specific survival (CSS) with HI and various factors.
FINDINGS
RESULTS
We studied a multiracial cohort of 15,532 Stage 0-IV breast cancer patients. Median age was 53.7 years and median follow-up was 7.7 years. Patients with lower HI presented with more advanced disease and had lower treatment compliance. On multivariable analysis, compared to HI(high) patients, HI(med) patients had decreased OS (HR=1.14, 95% CI 1.05-1.23) and CSS (HR=1.15, 95% CI 1.03-1.27), and HI(low) patients demonstrated reduced OS (HR=1.16, 95% CI 1.01-1.33). Ten-year non-cancer mortality was higher in lower HI-strata. Enhanced medical subsidy approximately halved treatment noncompliance rates but its receipt was not an independent prognostic factor for survival.
INTERPRETATION
CONCLUSIONS
Despite good healthcare access, lower-HI patients have poorer survival from both cancer and non-cancer causes, possibly due to delayed health-seeking and poorer treatment compliance. Enhanced subsidies may mitigate socioeconomic disadvantages.
FUNDING
BACKGROUND
None.
Identifiants
pubmed: 34327401
doi: 10.1016/j.lanwpc.2020.100065
pii: S2666-6065(20)30065-1
pmc: PMC8315650
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100065Informations de copyright
© 2020 The Author(s). Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
We declare no competing interests.
Références
Breast Cancer Res Treat. 2018 Jan;167(1):1-8
pubmed: 28884392
Sci Rep. 2020 Jan 28;10(1):1330
pubmed: 31992769
Int J Equity Health. 2018 Apr 02;17(1):39
pubmed: 29609592
Hypertens Res. 2012 Mar;35(3):295-303
pubmed: 22089533
PLoS One. 2012;7(9):e46314
pubmed: 23050011
BMC Cancer. 2011 May 18;11:178
pubmed: 21586176
Cancer. 2017 Jun 1;123(11):1998-2005
pubmed: 28135397
Eur J Cancer. 2008 Sep;44(14):1996-2002
pubmed: 18701275
COPD. 2012 Jun;9(3):216-26
pubmed: 22497534
Lancet Public Health. 2020 Mar;5(3):e140-e149
pubmed: 32007134
BMC Cancer. 2009 Oct 14;9:364
pubmed: 19828016
Cancer Causes Control. 2006 Apr;17(3):287-97
pubmed: 16489536
Ann Surg. 2006 Feb;243(2):241-9
pubmed: 16432358
Cancer. 2011 Apr 1;117(7):1542-51
pubmed: 21425155
BMC Fam Pract. 2016 Feb 06;17:16
pubmed: 26851939
Cancer Med. 2020 Mar;9(5):1741-1752
pubmed: 31960609
Breast Cancer Res Treat. 2020 Feb;179(3):721-729
pubmed: 31735998
Ann Epidemiol. 2015 Aug;25(8):549-55
pubmed: 25795226
Breast Cancer Res Treat. 2018 Jul;170(2):405-414
pubmed: 29569018
Cancer. 2016 Mar 15;122(6):893-8
pubmed: 26696022
Ann Oncol. 2012 Mar;23(3):604-610
pubmed: 21586686
Clin Breast Cancer. 2019 Dec;19(6):e717-e722
pubmed: 31519450
Int J Equity Health. 2017 Oct 16;16(1):182
pubmed: 29037209
J Public Health (Oxf). 2014 Jun;36(2):205-12
pubmed: 23764393
J Clin Oncol. 2011 Oct 20;29(30):4014-21
pubmed: 21911717
PLoS One. 2014 Oct 01;9(10):e107630
pubmed: 25271739